Annual Current Liabilities
$12.60 M
+$356.00 K+2.91%
December 31, 2023
Summary
- As of February 26, 2025, BRNS annual total current liabilities is $12.60 million, with the most recent change of +$356.00 thousand (+2.91%) on December 31, 2023.
- During the last 3 years, BRNS annual current liabilities has risen by +$4.96 million (+64.87%).
- BRNS annual current liabilities is now at all-time high.
Performance
BRNS Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$15.07 M
-$517.00 K-3.32%
September 30, 2024
Summary
- As of February 26, 2025, BRNS quarterly total current liabilities is $15.07 million, with the most recent change of -$517.00 thousand (-3.32%) on September 30, 2024.
- Over the past year, BRNS quarterly current liabilities has stayed the same.
- BRNS quarterly current liabilities is now -18.83% below its all-time high of $18.57 million, reached on September 30, 2023.
Performance
BRNS Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
BRNS Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +2.9% | 0.0% |
| 3 y3 years | +64.9% | +23.1% |
| 5 y5 years | +119.0% | +76.4% |
BRNS Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +12.9% | -18.8% | +35.1% |
| 5 y | 5-year | at high | +119.0% | -18.8% | +136.5% |
| alltime | all time | at high | +119.0% | -18.8% | +136.5% |
Barinthus Biotherapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $15.07 M(-3.3%) |
| Jun 2024 | - | $15.59 M(+21.5%) |
| Mar 2024 | - | $12.84 M(+1.9%) |
| Dec 2023 | $12.60 M(+2.9%) | $12.60 M(-32.2%) |
| Sep 2023 | - | $18.57 M(+53.3%) |
| Jun 2023 | - | $12.11 M(+1.0%) |
| Mar 2023 | - | $11.99 M(-2.1%) |
| Dec 2022 | $12.24 M | $12.24 M(-12.8%) |
| Sep 2022 | - | $14.03 M(+15.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $12.17 M(-26.2%) |
| Mar 2022 | - | $16.48 M(+47.7%) |
| Dec 2021 | $11.16 M(+46.0%) | - |
| Dec 2021 | - | $11.16 M(+75.1%) |
| Sep 2021 | - | $6.37 M(-25.4%) |
| Jun 2021 | - | $8.54 M(-1.2%) |
| Mar 2021 | - | $8.65 M(+13.2%) |
| Dec 2020 | $7.64 M(+32.8%) | $7.64 M |
| Dec 2019 | $5.75 M | - |
FAQ
- What is Barinthus Biotherapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics annual current liabilities year-on-year change?
- What is Barinthus Biotherapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics quarterly current liabilities year-on-year change?
What is Barinthus Biotherapeutics annual total current liabilities?
The current annual current liabilities of BRNS is $12.60 M
What is the all time high annual current liabilities for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high annual total current liabilities is $12.60 M
What is Barinthus Biotherapeutics annual current liabilities year-on-year change?
Over the past year, BRNS annual total current liabilities has changed by +$356.00 K (+2.91%)
What is Barinthus Biotherapeutics quarterly total current liabilities?
The current quarterly current liabilities of BRNS is $15.07 M
What is the all time high quarterly current liabilities for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high quarterly total current liabilities is $18.57 M
What is Barinthus Biotherapeutics quarterly current liabilities year-on-year change?
Over the past year, BRNS quarterly total current liabilities has changed by $0.00 (0.00%)